Understanding how T-LGL leukemia resists treatment and finding new therapies
Mechanisms of Resistance and Therapeutic Targets in T-LGL Leukemia
['FUNDING_R03'] · OHIO STATE UNIVERSITY · NIH-11004692
This study is looking at a rare type of blood cancer called T-cell large granular lymphocytic leukemia (T-LGLL) to understand why some treatments don't work well and to find new options, especially ones that target a substance called interleukin-15, which plays a big role in the disease, so that patients can have better outcomes and rely less on treatments that weaken their immune system.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11004692 on ClinicalTrials.gov |
What this research studies
This research focuses on T-cell large granular lymphocytic leukemia (T-LGLL), a rare and challenging blood cancer that leads to severe anemia and recurrent infections. The study aims to investigate the underlying mechanisms of resistance to current therapies and explore new targeted treatments, particularly those that inhibit interleukin-15 (IL-15), a key driver of the disease. By analyzing patient responses to a specific peptide therapy, the research seeks to identify effective strategies to improve patient outcomes and reduce reliance on less effective immune-suppressive treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL) who are experiencing severe symptoms such as anemia and recurrent infections.
Not a fit: Patients with other types of leukemia or those who do not have T-LGLL may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective therapies for T-LGLL, significantly improving patient quality of life and survival rates.
How similar studies have performed: Previous research has shown some success in targeting IL-15 in similar conditions, indicating potential for this approach in T-LGLL.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRAMMER, JONATHAN EDWARD — OHIO STATE UNIVERSITY
- Study coordinator: BRAMMER, JONATHAN EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases, autoimmune disorder, autoimmunity disease